Robotic-assisted Vs Video-assisted lobectomy for early-stage lung cancer

Dr. Patel and colleagues reported that the study sought to determine the difference in patient-reported health-related quality of life (HRQOL) between robot-assisted surgery and video-assisted surgery at 12 weeks after surgery and incremental cost per quality-adjusted life year (QALY) at 12 months after surgery.

Dr. Patel, from four academic sites in the United States, Canada, and France enrolled 406 patients with early-stage lung cancer who were candidates for minimally invasive lobectomy. Patients were randomized to receive either RTS-Lobectomy which is intervention or VATS-Lobectomy thats is control.

Patients were blinded to the type of surgery until the 12-month follow-up. Each patient completed questionnaires at baseline, postoperative day one, weeks three, seven, 12, and months six, and 12.

Of the 406 patients screened, 45.81% were randomized. At the final eligibility review, 82 were analyzed in the RTS arm and 83 in the VATS arm. All patients were followed for at least 12 months. The mean age was 67.36 and 66.67% were women. There were no significant differences in the body mass index, comorbidities, pulmonary function, smoking status, location of the tumor, tumor size, or disease stage between arms.

Based on the findings the authors said, "Early results of the RAVAL trial suggest that RTS-Lobectomy is a cost-effective intervention which is associated with better patient-reported HRQOL when compared to VATS-Lobectomy within 12 months of surgery and RTS-Lobectomy is also associated with superior lymph node sampling,"

Ref: Dr. Yogita S. Patel et. al, INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER, MEETING IASLC World Conference on Lung Cancer 2022, 9-AUG-2022